Invivyd, Inc. (IVVD) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Invivyd, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:06.080 Thank you for standing by and welcome to InVivid's first quarter 2025 earnings 00:00:06.080 -- 00:00:11.648 conference call. At this time, all participants are in a listen-only mode. 00:00:11.648 -- 00:00:15.834 After the speaker presentation, there will be a question and answer session. 00:00:15.834 -- 00:00:20.862 To ask a question during the session, you will need to press star 1-1 on your telephone. 00:00:20.862 -- 00:00:24.327 To remove yourself from the queue, you may press star 1-1 again. 00:00:24.327 -- 00:00:30.288 I would now like to hand the call over to Katie Fazzoni, SVP Finance. 00:00:30.288 -- 00:00:32.711 Please go ahead. 00:00:32.711 -- 00:00:37.918 Thank you, Operator. A short while ago, we issued a press release announcing our Q1 2025 00:00:37.918 -- 00:00:40.942 financial results and business highlights. 00:00:40.942 -- 00:00:45.067 That press release and the slides that are being used on today's webcast can be found 00:00:45.067 -- 00:00:49.313 in the investor section of the InVivid website under the press release and events and 00:00:49.313 -- 00:00:52.236 presentation sections respectively. 00:00:52.236 -- 00:00:57.283 Today's discussion will be led by Mark Olia, Chairman of InVivid's Board of Directors. 00:00:57.283 -- 00:01:02.205 He is joined by Tim Lee, Chief Commercial Officer, Bill Duke, Chief Financial Officer, 00:01:02.205 -- 00:01:05.409 Dr. Robert Allen, Chief Scientific Officer, and Dr. 00:01:05.409 -- 00:01:09.733 Mark Wingertzahn, Senior Vice President of Clinical Development. 00:01:09.733 -- 00:01:14.038 During today's discussion, we will be making forward-looking statements concerning, among 00:01:14.038 -- 00:01:18.823 other things, our corporate and commercial strategy, our research and devel...